ALZN
Alzamend Neuro, Inc.
Next earnings Jul 20, 2026 (before open) · consensus $-0.68 EPS
$1.20
▲ 0.00%$1.20▼ -59.32%
over 1Y
L $0.86EODHDH $3.53
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W-1.6%
1M+4.3%
3M+14.3%
YTD-36.8%
1Y-59.3%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity 0.16x).
Return on equity -113.8% · latest
Alzamend Neuro, Inc. shows limited reported revenue, and -113.8% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$4.95M | -$12.3M | -$14.9M | -$9.94M | -$4.50M |
| Net income | -$5.05M | -$12.4M | -$14.9M | -$9.95M | -$4.51M |
| Diluted EPS | — | -$0.14 | -$22.89 | -$132.33 | -$11.32 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$473K
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-129.9%
FCF yield—
Quality & risk
ROIC (est.)-89.5%
Free cash flow—
Total debt—
Net cash$3.95M
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+244.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — delisting notice (2026-03-20). Worth a closer look.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-04-172026-04-17open ↗4Period ending 2026-04-142026-04-16open ↗8-KPeriod ending 2026-03-202026-03-20open ↗10-QPeriod ending 2026-01-312026-03-11open ↗424B5Filing2026-03-06open ↗8-KPeriod ending 2026-03-062026-03-06open ↗DEFA14AFiling2026-02-26open ↗DEF 14APeriod ending 2026-04-172026-02-26open ↗PRE 14APeriod ending 2026-04-172026-02-09open ↗4Period ending 2025-12-232025-12-30open ↗4Period ending 2025-12-192025-12-23open ↗10-QPeriod ending 2025-10-312025-12-09open ↗
Frequently asked
- Is Alzamend Neuro, Inc. (ALZN) a buy?
- ALZN currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.16x).
- What is Alzamend Neuro, Inc.'s quality score?
- ALZN scores 59.87179487179487/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001677077, latest 10-Q filed 2026-03-11) · EODHD · as of 6/26/2026, 7:22:34 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.